Johnson & Johnson operates as an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company, through its subsidiaries operates in three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The baby care franchise includes the JOHNSON'S Baby line of products. Major brands in the skin care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; DABAO; and VEND‘ME product lines. Brands in the oral care franchise include the LISTERINE and REMBRANDT oral care lines, as well as REACH interdental products. The wound care franchise includes BAND-AID brand adhesive bandages and NEOSPORIN First Aid products. Major brands in the women's health franchise are CAREFREE pantiliners; o.b. tampons and STAYFREE sanitary protection products. The principal nutritional line is SPLENDA No Calorie Sweetener. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC line of heartburn products. The Pharmaceutical segment includes products in the anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines. The products in this segment include REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO (telaprevir), for the treatment of hepatitis C; INTELENCE (etravirine) and PREZISTA (darunavir), treatments for HIV/AIDS; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA /XEPLION (paliperidone palmitate), for the treatment of schizophrenia in adults; RISPERDAL CONSTA (risperidone), for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE (bortezomib), a treatment for multiple myeloma; ZYTIGA (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; ACIPHE /PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT (epoetin alfa, sold outside the U.S. as EPREX), to stimulate red blood cell production; and XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. These include products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. Johnson & Johnson was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.